Antibiotics

Published by: Global Industry Analysts

Published: May. 1, 2008 - 787 Pages

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations

Disclaimers

Data Interpretation & Reporting Level

Quantitative Techniques & Analytics

Product Definitions and Scope of Study

Penicillin

Cephalosporins

Macrolides

Quinolones

Carbapenems

Other Antibiotics

Aminoglycosides

Tetracyclines

Sulfonamides

Mupirocin

Glycopeptides

Synercid

Oxazolidinones

Linezolid

II. EXECUTIVE SUMMARY

1. Industry Overview

Antibiotic Resistance and Generic Competition to Impact Long Term Growth

Current & Future Analysis

2. Market Dynamics

Anti-Bacterials Segment Drives Global Anti-Infectives Market

Antibiotic Resistance - A Primary Growth Inhibitor

Antibiotic-Resistant Bacteria by Type

Patent Expiries Commoditize Antibiotics

Patent Expiries of Leading Drugs in the Recent Past, Current, and Future

Anti-MRSA Antibiotics Find Their Way

Table 1: Estimated Revenues Generated by Leading MRSA Antibiotic Drugs in 2005 (includes corresponding Graph/Chart)

Key Antibiotics in Pipeline

3. Competition

Highly Competitive Market

Table 2: Leading Players in the Worldwide Antibiotics Market (2006): Percentage Breakdown by Value Sales for Pfizer, Glaxo Smithkline, Sanofi-aventis, Johnson & Johnson, Bayer, Abbott, Wyeth, and Others (includes corresponding Graph/Chart)

GlaxoSmithKline - The Undisputed Leader of Penicillin Market

Table 3: Worldwide Leading Antibiotics within Penicillin Class (2005 & 2006): Percentage Breakdown by Value for Augmentin, Zosyn/Tazocin, Amoxil, and Others (includes corresponding Graph/Chart)

GlaxoSmithKline Leads Cephalosporin Market

Table 4: Worldwide Leading Antibiotics within Cephalosporin Class (2005 & 2006): Percentage Breakdown by Value for Rocephin, Ceftin/Zinnat, Flomox, Fortum/Fortaz, Cefzil, Cefzon, Flumarin, and Others (includes corresponding Graph/Chart)

Pfizer Dominates Macrolides Market

Table 5: Worldwide Leading Antibiotics within Macrolide Class (2005 & 2006): Percentage Breakdown by Value for Zithromax, Klaricid/Biaxin, Ketek, and Others (includes corresponding Graph/Chart)

Levaquin/Tavanic - The Most Preferred Quinolone Antibiotic

Table 6: Worldwide Leading Antibiotics within Quinolone Class (2005 & 2006): Percentage Breakdown by Value for Levaquin/Tavanic, Avelox, Ciprobay/Ciproxin, Cravid, and Others (includes corresponding Graph/Chart)

Merck Rules Carbapenems Market

Table 7: Worldwide Leading Antibiotics within Carbapenem Class (2005 & 2006): Percentage Breakdown by Value for Primaxin, Merrem, Invanz, and Others (includes corresponding Graph/Chart)

4. Product Overview

Antibiotics - An Introduction

Antibiotic Resistance

ß -Lactams

Classification of Antibiotics

Key Milestones in Antibiotic Development

Antibiotic Types

Penicillin

History

About the Drug

Cephalosporins

Treatment

Effects of the Drug

Macrolides

Treatment

Quinolones

Carbapenems

Other Antibiotics

Aminoglycosides

Treatment

Effects of the Drug

Tetracyclines

Treatment

Effects of the Drug

Sulfonamides

Treatment

Effects of the Drug

Mupirocin

Glycopeptides

Synercid

Oxazolidinones

Linezolid

5. Research Findings

Cephalosporins Effective when Compared to Penicillin

FDA Bans Baytril Antibiotic for Chickens

Erythromycin Along with Some Specific Drugs Increase Risk of Sudden Death

Rise in Usage of Quinolones for Urinary Tract Infections Leads to Drug

Resistance

6. FDA Approvals/Patents

MiddleBrook Obtains NDA Approval for MOXATAG™

J&JPRD Seeks FDA Approval for Doripenem Antibiotic

J&JPRD Seeks FDA Approval for Investigational Antibiotic, Ceftobiprole

GSK Receives Approval for ALTARGO® in Europe

APL Receives FDA Approval for Cefpodoxime Proxetil

Cubist Receives Approval to Market CUBICIN in Canada

Cubist Obtains Approval to Market CUBICIN for Added Indications in EU

Cubist Gains Approval for CUBICIN in Taiwan and South Korea

Cethromycin Achieves FDA’s Orphan Drug Designation

FDA Approves Wockhardt’s Cefotaxime Injection

FDA Approves Doxycycline Tablets

FDA Approves Clarithromycin

FDA Approves Doxycycline Tablets For The US Market

Johnson & Johnson Applies Doripenem For FDA Approval

FDA Certifies Antibioticos do Brasil’s Plant

FDA Certifies ANDA For Cefdinir Capsules

US FDA Approves Teva’s Cefprozil Tablets

FDA Certifies ANDA for Cephalexin Capsules

American Pharmaceutical Partners Receives FDA Approvals for Ceftriaxone for Injection,

USP

Advancis’s Keflex Receives FDA Approval

Wockhardt Gains Marketing Approval for Cefuroxime axetil in the US

Wyeth’s Mylotarq Receives Government’s Approval

FDA Approves Generic Version of Zithromax

Pfizer Wins FDA Approval for Zmax™

Venus Remedies Files Second PCT for New Cephalosporins

Falcon Gains US FDA Approval for its Generic Anti-Infective Solution

Cadilla Receives FDA Approval to Market Clindamycin

7. Recent Industry Activity

3i to Buy Alpharma Unit

NCPC to Acquire Stake in DSM’s Antibiotics Division

ULL Establishes New Antibiotics Unit in Himachal Pradesh

Biocat to Expand Presence in the Indian Market

PRWT Acquires Cherokee Chemical Unit from Merck

CSPC Joins Hands with Indonesian Firms

Nisshin-Kyorin to Merge with Kyorin Pharmaceutical

Schering-Plough Acquires Organon BioSciences

GSK & Anacor Partner for Boron Chemistry-Based Antibiotics and Antivirals

Iroko Bags Canadian Rights to Vancocin®

Cubist Licenses CUBICIN Rights to Merck

Sagent Partners with Astral to Develop Injectable Antibiotics

MR Healthcare to Manufacture New Antibiotics & Medicines

Livzon Synthetic to Acquire Antibiotic Intermediate from Jiaozuo

C&O Pharmaceutical to Distribute Meiact in China

Bioton Signs Deal to Market Antibiotics in Russia

Toyama Gains Marketing Approval for Geninax® in Japan

Forest Laboratories Acquires Cerexa

Oscient Modifies Licensing Agreement With LG Life Sciences

Orchid Sign Licensing & Distribution Pact With Actavis

Forest Laboratories Revokes Partnership With Replidyne

SRI and Blanca Collaborate To Develop & Test Carbacephem

AstraZeneca To Expand Research Center For Antibiotics

Jade Pharmaceutical Begins Levofloxacin’s Production in China

Reyoung To Start Antibiotic Production At New Facility

Toyama Begins T-705 Clinical Trials

SmPC For Sanofi-Aventis’ Ketek® Updated

Lupin Receives Approval for Cefpodoxime Proxetil Antiobiotic Tablets in France

Antibiotice Plans To Infuse Funds For Antibiotics Production

UAE Approves Pfizer’s Zithromax SD

Premier Takes Over Cereplex

Laboratorios Roemmers Acquires Argentine Pharmaceutical’s Business

Ranbaxy Adds Be-Tabs

AstraZeneca Purchases Vancocin® From Eli Lilly

Ranbaxy Laboratories Limited Acquires Ethimed NV

Ranbaxy Laboratories Limited Acquires Terapia SA

Ranbaxy Italia Acquires Allen Generic Business of GlaxoSmithKline

Connetics Acquires Sales Organization of PediaMed

Wyeth Increases Stake in Wyeth KK to 80%

Sankyo Pharma, Daiichi Medical Research and Daiichi Pharmaceutical Merge

Merck & Co. and Paratek Sign Development & License Pact

Wakunga and Rib-X Sign Licensing Pact

Pfizer Settles Infringement Lawsuit With Teva

Astellas Extends Agreement With Theravance

Astellas and Theravance Sign Collaboration Agreement

Cubist and AstraZeneca Sign License Pact

Astellas Pharma and Sanofi-Aventis Revoke Marketing Pact

Achaogen Bags Licensing Agreement from Isis

Pfizer Bags Rights from Oscient to Market Antibiotic in Mexico

Replidyne Enters into Licensing Agreement with Forest Laboratories

Toyama Chemical Co Ltd Enters into Licensing Agreement with Astellas Pharma

AVAS’ Majority Stake To Be Sold

NIH Grants US$3 Million To PolyMedix For Antibiotics

Wyeth’s Tygacil Achieves European Approval

Chiron’s Cubicin® Receives Marketing Grant In The EU

Vietnam Bans Antibiotics In Aquaculture

Sance Pharmaceuticals Establishes Sance Laboratories

Caps Holdings Plans to Re-enter Penicillin Market

Alkem Establishes Sterile Cephalosporin Unit

Novartis Completes Chiron Acquisition

Toyama Submits New Drug Application For Quinolone Antibiotic Compound

China Pharma Receives GMP Certification For Cephalosporin Antibiotic

Production

Venus Remedies Files For FDC Approval

Sankyo Acquires rival Daiichi Pharmaceutical for US$ 7 Billion

Daiichi Pharmaceutical Takes Over Daiichi Suntory Pharma

Pfizer Acquires Idun Pharmaceuticals

Pfizer Acquires Vicuron Pharmaceuticals

Pfizer Acquires Bioren

Novartis Acquires Eon Labs

Kyorin Pharmaceutical Acquires Stake in Toyo Pharmar

Targanta Acquires InterMune’s Late-Stage Antibiotic

Novartis Acquires Hexal

TB Alliance and Bayer Partner in Clinical Trials

SBC Communications Enters into Agreement with Pfizer for Managed Voice

Services

Vicuron Extends Oral Antibiotics Development Agreement With Pfizer

Orchid Chemicals Signs Distribution Agreement with Mayne Pharma

Cubist Pharmaceuticals Inks Agreement with ACS Dobfar

Orchid Chemicals Inks Marketing Agreement with Alpharma

Lupin and DSM Anti-Infectives Sign Agreement to Market Cephalosporins

Ranbaxy to Market P&G’s Generic Drug

Nectar Expands Capacity

Novartis Establishes Novartis Holding Japan

Sun Pharma Acquires Phlox Pharma

Kyorin Takes Over ActivX

Advancis Acquires Lilly’s Keflex Brand

Enanta Enters into Partnership with Shionogi & Co

Toyama Signs Collaborative Agreement with Glaxo to Develop Antibacterial

Agents

Enanta and Shionogi Ink an Agreement to Market EP- 013420

Orchid Inks Agreement with Apotex to Market Generic Antibiotics

Toyama Signs Licensing Agreement for TN-3262a with Dong-A

Toyama Inks License Agreement with Schering for T-3811

Shionogi Wins Rights to Market Cedax in the US

Connetics Enters Acne Market

8. Product Innovations/Introductions

MIT Scientists Develop a New Antibiotic, Rhodostreptomycin

Watson Pharma Introduces Biaxin XL’s Generic Version

Toyama Launches New Garenoxacin Quinolone Antibiotic

Wockhardt to Introduce Cefprozil in the US

MSD India Launches Invanza in India

Orchid Chemicals to Introduce Three New Drugs in the US

DUSA Pharmaceuticals Releases ClindaReach™

Mylan Releases Cipro’s Generic Version

Macrolide Antibiotic Developed In the US

University of Michigan Devises NMR Spectroscopy For Antibiotics

Glycopeptide-Cephalosporin Antibiotics Developed In The US

Neosil Tests NEO 101 Antibiotic

New Antibiotic Developed By Canadian Inventors

Abbott Canada Releases FACTIVE® Antibiotic Tablets In Canada

Pencillin Binding Protein Found In Japan

Venus Remedies Releases Mucomelt-Forte

Baxter Launches Injectable Antibiotic, Zithromax

Advancis Releases Keflex (750mg) Capsules

Researchers Develop Antibiotic For MRSA

Wyeth Releases Tygacil In The UK

Nihon Pharmaceutical Releases Clarithomycin Antibiotic

Daiichi Sankyo Engages In Quinolone Antibiotic Development

Shionogi Commercializes Finibax

Sandoz and Nomura Phase4 Ventures Launch Nabriva Therapeutics Forschungs GmbH

Lilly’s Investigational Cancer Agent Reaches Phase III Clinical Trial

Idemitsu Technofine Launches Antibacterial Product

Galleon Develops Oral Aminoglycoside Antibiotic

Advancis Introduces Keflex® Powder in the US

Skin Test for Penicillin Comes Back into the Market

Cubist Introduces New Registry Program

Idemitsu Technofine Launches Antibacterial Product

9. Focus on Select Global Players

Abbott Laboratories (USA)

MiddleBrook™ Pharmaceuticals, Inc. (USA)

Bayer HealthCare AG (Germany)

Bristol-Myers Squibb Co. (USA)

Cubist Pharmaceuticals, Inc. (USA)

Daiichi Sankyo Company, Limited (Japan)

Eli Lilly and Co. (USA)

GlaxoSmithKline Plc (UK)

Johnson & Johnson (USA)

Kyorin Pharmaceutical Co., Ltd. (Japan)

LG Life Sciences Limited (Korea)

MiddleBrook™ Pharmaceuticals, Inc. (USA)

Novartis AG (Switzerland)

Pfizer Inc. (USA)

Pliva d.d. (Croatia)

Roche (Switzerland)

Sanofi-Aventis SA (France)

Takeda Pharmaceutical Company, Ltd. (Japan)

Toyama Chemical Co., Ltd. (Japan)

Wyeth Pharmaceuticals, Inc. (USA)

10. Global Market Perspective

Table 8: World Recent Past, Current & Future Analysis for Antibiotics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 9: World Long-term Projections for Antibiotics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 10: World 10-Year Perspective for Antibiotics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)

Table 11: World Recent Past, Current & Future Analysis for Penicillin by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 12: World Long-term Projections for Penicillin by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 13: World 10-Year Perspective for Penicillin by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)

Table 14: World Recent Past, Current & Future Analysis for Cephalosporin by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 15: World Long-term Projections for Cephalosporin by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 16: World 10-Year Perspective for Cephalosporin by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)

Table 17: World Recent Past, Current & Future Analysis for Macrolides by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 18: World Long-term Projections for Macrolides by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 19: World 10-Year Perspective for Macrolides by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)

Table 20: World Recent Past, Current & Future Analysis for Quinolones by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 21: World Long-term Projections for Quinolones by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 22: World 10-Year Perspective for Quinolones by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)

Table 23: World Recent Past, Current & Future Analysis for Carbapenems by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 24: World Long-term Projections for Carbapenems by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 25: World 10-Year Perspective for Carbapenems by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)

Table 26: World Recent Past, Current & Future Analysis for Other Antibiotics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 27: World Long-term Projectionsfor Other Antibiotics by Geographic Region - US, Canada, Jap an, Europe, Asia- Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 28: World 10-Year Perspective for Other Antibiotics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)

III. MARKET

1. The United States

A. Market Analysis

Current and Future Analysis

Antibiotics Approved Between 2000 and 2005 in the United States

Competition

Table 29: Leading Players in the US Antibiotics Market (2006): Percentage Breakdown by Value Sales for Pfizer, Johnson & Johnson, GlaxoSmithKline, Abbott, and Others (includes corresponding Graph/Chart)

Strategic Corporate Developments

Product Introductions/Innovations

FDA Approvals / Patents

Focus on Select Players

B. Market Analytics

Table 30: US Recent Past, Current & Future Analysis for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 31: US Long-term Projections for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics MarketsIndependently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 32: US 10-Year Perspective for Antibiotics by Product Segment - Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

2. Canada

Market Analysis

Current And Future Analysis

Strategic Corporate Developments

Product Introductions/Innovations

Table 33: Canadian Recent Past, Current & Future Analysis for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 34: Canadian Long-term Projections for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 35: Canadian 10-Year Perspective for Antibiotics by Product Segment - Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

3. Japan

A. Market Analysis

Current and Future Analysis

Strategic Corporate Developments

Product Introductions/Innovations

Focus on Select Players

B. Market Analytics

Table 36: Japanese Recent Past, Current & Future Analysis for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 37: Japanese Long-term Projections for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 38: Japanese 10-Year Perspective for Antibiotics by Product Segment - Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

4. Europe

A. Market Analysis

Current and Future Analysis

Strategic Corporate Developments

B. Market Analytics

Table 39: European Recent Past, Current & Future Analysis for Antibiotics by Geographic Region - France, Germany, Italy, UK, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 40: European Long-term Projections for Antibiotics by Geographic Region - France, Germany, Italy, UK, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 41: European Recent Past, Current & Future Analysis for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems, and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 42: European Long-term Projections for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems, and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 43: European 10-Year Perspective for Antibiotics by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, and Rest of Europe Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

Table 44: European 10-Year Perspective for Antibiotics by Product Segment - Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems, and Other Antibiotics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

4a. France

A. Market Analysis

Current and Future Analysis

Trends

Over Consumption of Antibiotics - Cause of Concern

Strategic Corporate Developments

Sanofi-Aventis SA - A Key Player

B. Market Analytics

Table 45: French Recent Past, Current & Future Analysis for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 46: French Long-term Projections for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 47: French 10-Year Perspective for Antibiotics by Product Segment - Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets for2003, 2008 & 2012 (includes corresponding Graph/Chart)

4b. Germany

A. Market Analysis

Current and Future Analysis

Strategic Corporate Developments

Bayer HealthCare AG - A Key Player

B. Market Analytics

Table 48: German Recent Past, Current & Future Analysis for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 49: German Long-term Projections for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 50: German 10-Year Perspective for Antibiotics by Product Segment - Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

4c. Italy

A. Market Analysis

Current and Future Analysis

Corporate Development

B. Market Analytics

Table 51: Italian Recent Past, Current & Future Analysis for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 52: Italian Long-term Projections for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 53: Italian 10-Year Perspective for Antibiotics by Product Segment - Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

4d. The United Kingdom

Market Analysis

Current And Future Analysis

Product Introduction

GlaxoSmithKline Plc - A Key Player

Table 54: UK Recent Past, Current & Future Analysis for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 55: UK Long-term Projections for Antibiotics by Product Segment - Penicillin, Cephalosporin, acrolides, Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 56: UK 10-Year Perspective for Antibiotics by Product Segment - Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets for2003, 2008 & 2012 (includes corresponding Graph/Chart)

4e. Spain

Market Analysis

Table 57: Spanish Recent Past, Current & Future Analysis for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 58: Spanish Long-term Projections for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 59: Spanish 10-Year Perspective for Antibiotics by Product Segment - Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

4f. Rest of Europe

A. Market Analysis

Current and Future Analysis

Strategic Corporate Developments

Product Launch

Focus on Select Players

B. Market Analytics

Table 60: Rest of Europe Recent Past, Current & Future Analysis for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 61: Rest of Europe Long-term Projections for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 62: Rest of Europe 10-Year Perspective for Antibiotics by Product Segment - Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

5. Asia-Pacific

A. Market Analysis

Current and Future Analysis

India

Rising Prices of Penicillin G to Affect Antibiotics Production

Strategic Corporate Developments

Product Introduction

FDA Approvals / Patents

Focus on Select Players

B. Market Analytics

Table 63: Asia-Pacific Recent Past, Current & Future Analysis for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 64: Asia-Pacific Long-term Projections for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 65: Asia-Pacific 10-Year Perspective for Antibiotics by Product Segment - Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

6. Rest of World

A. Market Analysis

Current and Future Analysis

Strategic Corporate Developments

B. Market Analytics

Table 66: Rest of World Recent Past, Current & Future Analysis for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 67: Rest of World Long-term Projections for Antibiotics by Product Segment - Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 68: Rest of World 10-Year Perspective for Antibiotics by Product Segment - Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 205 (including Divisions/Subsidiaries - 244)

Region/Country Players

The United States 50

Canada 8

Japan 11

Europe 65

France 7

Germany 10

The United Kingdom 8

Italy 10

Spain 4

Rest of Europe 26

Asia-Pacific (Excluding Japan) 95

Middle East 10

Latin America 4

Africa 1

Abstract

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.